Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ARID3A CRISPR/Cas9 KO Plasmid (h): sc-404552
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ARID3A CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ARID3A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ARID3A Antibody (A-4): sc-398367
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ARID3A CRISPR/Cas9 KO Plasmid (h) | sc-404552 | 20 µg | $397.00 |
Overview
ARID3A (AT-rich interaction domain 3A) is a DNA-binding transcription factor that regulates chromatin accessibility and lineage-specific gene expression programs. In hematopoietic systems it is strongly linked to B-cell development and immunoglobulin gene regulation, integrating with transcriptional networks that coordinate differentiation, proliferation, and apoptosis. ARID3A activity influences epigenetic control of target loci and can affect cellular responses to developmental and stress cues. Dysregulated ARID3A expression or function has been associated with altered immune cell phenotypes and has been studied in contexts including hematologic malignancy and autoimmunity.
ARID3A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ARID3A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ARID3A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ARID3A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ARID3A protein expression.
This CRISPR knockout system enables efficient generation of ARID3A-deficient cell models for investigation of ARID3A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ARID3A exon(s) critical for ARID3A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ARID3A genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ARID3A CRISPR/Cas9 KO Plasmid (h) and ARID3A CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ARID3A locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ARID3A HDR Plasmid (h) and ARID3A HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ARID3A homology arms to support homology-directed repair at defined ARID3A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.